Primary Biliary Cholangitis Therapeutics Market Expected to Reach $1.4 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Primary Biliary Cholangitis Therapeutics Market," The primary biliary cholangitis therapeutics market size was valued at $683.95 million in 2022, and is estimated to reach $1.4 billion by 2032, growing at a CAGR of 7.1% from 2023 to 2032. 

Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic autoimmune liver disease. It primarily affects the small bile ducts within the liver, causing inflammation, damage, and ultimately, the destruction of these ducts. Primary biliary cholangitis therapeutics are the medications that help to slow the progression of the disease, improve liver function, and relieve symptoms. The ursodeoxycholic acid, obeticholic acid are the U.S. Food and Drug Administration (FDA) approved drug for the treatment of primary biliary cholangitis. In cases where these medications are not effective or the disease progresses despite treatment, liver transplantation may be considered as a last resort option.

In addition, recently PPARα/PPARδ agonist, and ileal bile acid transport (IBAT) inhibitors have also evolved as effective therapeutics for the treatment of primary biliary cholangitis. The antihistamines, cholestyramine, rifampin, sertraline, and opioid antagonists are used as an adjunctive therapy to alleviate itching (pruritus) associated with primary biliary cholangitis.

Alarming rise in the in cases of primary biliary cholangitis, as well as increase in number of research regarding primary biliary cholangitis drives the growth of primary biliary cholangitis therapeutics market share. For instance, in June 2022, GSK plc presented 12 abstracts at the European Association for the Study of the Liver’s International Liver Congress 2022 in London. presence focuses of GSK on novel investigational specialty medicines, linerixibat, an ileal bile acid transporter (IBAT) inhibitor for cholestatic pruritus in primary biliary cholangitis (PBC). This year, new data is being shared in International Liver Congress, to deliver novel medicines for patients with significant unmet medical need, such as those who suffer from cholestatic pruritus in primary biliary cholangitis.

Moreover, the increase in initiatives taken by various organizatons for reducing the burden of the diseases and rise in number of clinical trials of primary biliary cholangitis therapeutics drive the growth of primary biliary cholangitis therapeutics market share. For instance, in December 2021, Cadila Healthcare Limited (Zydus Cadila) received permission from the U.S. Drug regulator, U.S. Food and Drugs Administration (USFDA) to initiate Phase 2(b)/3 clinical trials to evaluate the efficacy and the safety of Saroglitazar Magnesium in patients with primary biliary cholangitis (PBC). PBC is a liver disease causing liver complications, which even leads to death in some cases. The EPICS-IIITM trial is expected to randomize 192 subjects in a 1:1:1 ratio to Saroglitazar 1 mg, Saroglitazar 2 mg or Placebo and is anticipated to study the Saroglitazar Magnesium (1 or 2 mg) relative to Placebo, Zydus said in a statement. The rise in the number of clinical trials for the development of medicine for primary biliary cholangitis is expected to boost the growth of primary biliary cholangitis market.

In addition, rise in funding to conduct RD activities for the development of novel primary biliary cholangitis therapeutics, increase in awareness regarding primary biliary cholangitis is the key factor that drives the growth of the primary biliary cholangitis therapeutics market size in developing countries such as India and China.

Moreover, rise in R&D investments; significant increase in capital income in developed countries; and adoption of developmental strategies such as product launch, collaboration, merger, acquisition, and agreement by key players to stay competitive in the market are the major primary biliary cholangitis therapeutics market trends. For instance, in December 2021, Ipsen and Genfit entered a long-term strategic partnership in which Genfit has given Ipsen exclusive worldwide license to develop, manufacture, and commercialize its experimental late-stage treatment elafibranor, for people living with primary biliary cholangitis. The partnership also gives Ipsen access to future clinical programs led by Genfit and combines scientific expertise and proprietary technologies in liver disease of Genfit with development and commercialization capabilities of Ipsen.

On the basis of drug type, the primary drug segment is expected to witness the highest CAGR during the forecast period in primary biliary cholangitis therapeutics industry, owing to rise in patient suffering from PBC and availability of various primary drugs in pipeline.

On the basis of distribution channel, the online pharmacies segment is expected to witness the highest CAGR during the primary biliary cholangitis therapeutics market forecast period, owing to convenience in shopping, increase in e-commerce sales, improvements in logistics services, and ease in payment options. In addition, the easy accessibility and heavy discounts & offer provided by these online platforms drives the growth of online pharmacies during forecast period.

On the basis of region, Asia-Pacific is expected to witness the highest CAGR during the forecast period in primary biliary cholangitis therapeutics industry due to increase in population, unmet medical demand, surge in healthcare expenditure, and increase in cases of primary biliary cholangitis.

Key findings of the study

• On the basis of drug type, the primary drug segment held the largest share in the primary biliary cholangitis therapeutics market analysis in 2022.
• On the basis of distribution channel, the drugs stores and retail pharmacies dominated the market in 2022.
• On the basis of region, Asia-Pacific is expected to witness the highest CAGR during the forecast period.